Skip to content

The Effectiveness and Safety of Bifidobacterium CECT7894 in the Treatment of Food Protein Allergy of Infants

The Effectiveness and Safety of Bifidobacterium CECT7894 in the Treatment of Food Protein Allergy of Infants

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036435
Enrollment
Unknown
Registered
2020-08-23
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

food protein allergy

Interventions

Experimental group:CECT7894
Control group:Blank

Sponsors

Ruijin Hospital North, Shanghai Jiao Tong University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 1 Years

Inclusion criteria

Inclusion criteria: 1. Aged 0-12 months children; 2. Food protein allergy diagnosed by clinician; 3. The legal guardian of the child signed an informed consent form and agreed to participate in the study; 4. The legal guardian of the child promises to abide by the research procedures and cooperate with the implementation of the whole process of research.

Exclusion criteria

Exclusion criteria: 1. The patient had used various probiotics within 1 month before the study; 2. The patient is allergic or intolerant to probiotics or its excipients; 3. Combined with abnormalities of liver and kidney function, nervous system, respiratory system, and coagulation; 4. Unstable vital signs; 5. Suffer from other underlying diseases; 6. The researchers believe that there are other reasons not suitable for selection.

Design outcomes

Primary

MeasureTime frame
weight;Height;

Countries

China

Contacts

Public ContactXinqiong Wang

Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine

wangxq1983@126.com+86 21 64370045-666102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026